Stocktoria
Co-Diagnostics, Inc. CODX
Co-Diagnostics, Inc. (CODX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $622,489 at a -7533.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: 0.77 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.41 |
| Retained earnings / assets | -3.248 |
| EBIT / assets | -2.027 |
| Equity / liabilities | 5.014 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | 1/9 | -16.26 | — | — |
| LYRA | Lyra Therapeutics, Inc. | 2/9 | — | — | — |
| PLSE | PULSE BIOSCIENCES, INC. | 2/9 | -10.11 | — | — |
| QTEX | QTREX Quantum Ltd. | 2/9 | — | — | — |
| SINT | Sintx Technologies, Inc. | 2/9 | — | — | — |
| FOFA | FAMILY OFFICE OF AMERICA, INC. | 2/9 | -13.31 | — | — |
| SKYA | SkyAI, Inc. | 3/9 | — | — | — |
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
FAQ
Is CODX financially healthy?
Co-Diagnostics, Inc.'s Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CODX pay a dividend?
No, Co-Diagnostics, Inc. does not currently pay a dividend.
How profitable is CODX?
In FY2025, Co-Diagnostics, Inc. had a net margin of -7533.6% and a return on equity of -227.3%.
Is CODX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Co-Diagnostics, Inc.: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.